Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-κB Pathway

Chun-Han Hou1
Chih-Hsin Tang2–5
Po-Chun Chen5–7
Ju-Fang Liu7,8

1Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei City, Taiwan; 2School of Medicine, China Medical University, Taichung, Taiwan; 3Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan; 4Chinese Medicine Research Center, China Medical University, Taichung, Taiwan; 5Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan; 6Translational Medicine Center, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan; 7Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan; 8School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan

Background: It is known that osteoarthritis (OA) pathogenesis involves inflammation that drives pathologic changes and that the matricellular protein, thrombospondin-2 (TSP2), is involved in angiogenesis, carcinogenesis, and inflammation. However, how TSP2 contributes to OA inflammatory processes is unclear.

Objective: The aim of current study was to elucidate whether TSP2 could promote interleukin-6 (IL-6), a pro-inflammatory cytokine, expression in osteoarthritis synovial fibroblasts (OASFs).

Methods: The synovial fibroblasts isolated from osteoarthritis and healthy donors were incubated with recombinant TSP2 to evaluate its effect in OA pathogenesis. The SFs were incubated with recombinant TSP2, followed by determining the IL-6 expression by qPCR and Western blot. After SFs were incubated with TSP2 for different time interval, the Western blot was performed to investigate the activation of signal pathway. The different strategies including neutralizing antibodies, siRNAs, and chemical inhibitors were used to discover the signal transduction in response to TSP2 incubation in OASFs. To evaluate the therapeutic potential of TSP2 in osteoarthritis, the anterior cruciate ligament transection (ACLT) in SD rats was performed in the presence or absence of TSP neutralizing antibody treatment.

Results: Our investigations have revealed that TSP2 promoted IL-6 expression in OASFs in a dose-dependent manner, especially in 30 and 100 ng/mL concentration (p < 0.05). Using different strategies including neutralizing antibodies, siRNAs, and chemical inhibitors, all of which attenuated signal pathway components in OASFs, we found evidence for the involvement of integrin α6β1, PI3K, Akt, and NF-κB in TSP2-mediated upregulation of IL-6 (p < 0.05). Finally, in the result of rat ACLT surgical model, we found that TSP2 neutralizing antibody had protective effects in cartilage destruction during OA progression.

Conclusion: Thrombospondin-2 plays an important role in osteoarthritis pathogenesis and provides an opportunity to deal with osteoarthritis.

Keywords: TSP2, osteoarthritis, integrin α6β1, IL-6

Introduction
The degenerative joint disease, osteoarthritis (OA), affects mainly people from middle-age onwards and most often affects the hands and knees, hips, and spine. There are also earlier forms of OA. The multifactorial etiology of OA includes occupational and nonoccupational (ie, joint injury, obesity, aging, and heredity) factors. OA joints are characterized by severe synovial inflammation, abrasive wear at the cartilage surface, thickening of the subchondral bone, and the development of osteophytes. Besides this, OA has been also described as a chronic inflammatory disease caused by an increase of inflammatory mediators. Major
contributing factors to the pathogenesis of OA include the extracellular matrix (ECM) degrading enzyme such as the matrix metalloproteinases (MMPs) and ADAMTS-5 (ADAM metallopeptidase with thrombospondin type 1 motif 5), the proinflammatory cytokines interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α), as well as Wnt signaling regulating bone formation and regeneration.8–11 Understanding the mechanisms responsible for the destruction of joint tissue in OA and identifying the key factors involved will identify new targets for therapy and enable the development of new therapies that not just treat the symptoms, but slow the disease progression.

Cartilage oligomeric matrix protein (COMP/thrombospondin [TSP]-5), a glycoprotein that belongs to the thrombospondin family, is one of the most studied markers of cartilage degradation as well as joint degeneration.12,13 An elevated level of COMP/TSP5 was found in serum and synovial fluid and associated with the degree of cartilage destruction and disease progression in osteoarthritis.14–16 Besides COMP/TSP5, the other members of the thrombospondin family are also associated with osteoarthritis progression. For instance, increased levels of TSP1 expression were found in human cartilage with early OA, as well as substantially reduced TSP1 synthesis and TSP1 protein staining in severe OA, compared with normal cartilage.17 The other report showed that TSP1 exhibited protective effects against osteoarthritis by indirect interaction with adipose stem cells, subsequently reducing inflammation of chondrocytes.18 TSP4 expression was found to upregulate in OA keen cartilage and associated with disease severity.19 These evidence reveal that the TSP family, a matricellular protein with various functions, has an important role in the homeostasis of chondrocyte as well as in OA pathogenesis.

The loss of cartilage tissue in OA is due to the degradation of the ECM, which is influenced in part by a lack of the matricellular protein TSP2, an essential component in the proper assembly of the ECM,20 endothelial cell proliferation, migration, and differentiation.21–23 TSP2-null mice exhibit connective tissue abnormalities including lax tendons and ligaments, abnormal collagen fibrils in the skin and tendons, and prolonged bleeding times.24 Embryonic tissues from TSP2-null mice reveal TSP2 expression in chondrogenic, osteogenic, vasculogenic cells, dermal fibroblasts, and other connective tissue-forming cells.25,26 In adult tissue, TSP2 is found almost solely in the pericellular environment of cells.24 Moreover, compared with normal littermates, increased numbers of endocortical osteoblasts in TSP2-null mice mean that they have thicker cortical bones, with higher endocortical bone formation rates and an overall increased periosteal mineralizing surface.27,28 Previous report provided evidence that TSP2 served as regulator of inflammation in rheumatoid arthritis.29 However, this study only provided pathologic evidence and clinical relevance of TSP2 in rheumatoid arthritis.

Although many evidences support a pathogenic role for the other members among the TSP family in arthritis, more remains to be clarified as to the molecular connections between TSP2 and arthritis. Here, we found increased expression of TSP2 in OASFs compared with NSFs. We also verified the therapeutic response of TSP2 neutralizing antibody by using in vivo OA model. These evidence provided potential for clinical application of TSP2 in OA.

### Materials and Methods

#### Materials

Invitrogen (Carlsbad, CA, USA) supplied fetal bovine serum (FBS; Cat. No. 26140079), Dulbecco’s Modified Eagle Medium (DMEM; Cat. No. 12100046), and Lipofectamine 3000 (Cat. No. L3000015). Corning (NY, USA) supplied all cell culture materials including dishes and well plates. Millipore (Billerica, MA, USA) supplied polyvinylidene difluoride (PVDF) membranes and chemiluminescent HRP Substrate (ECL). Santa Cruz Biotechnology (Santa Cruz, CA, USA) supplied antibodies against PI3K (Cat. No. sc-1637), Akt (Cat. No. sc-5298), IκB (Cat. No. sc-1643), IKKa/β (Cat. No. sc-7607), p65 (Cat. No. sc-8008), integrin a,b3 (Cat. No. sc-7312) and β-actin (Cat. No. sc-47778). The antibodies against phospho-PI3K (Tyr458/199) (Cat. No. #4228), phospho-Akt (ser473) (Cat. No. #9271), phospho-IKKα/β (ser176/180) (Cat. No. #2697), phospho-IkBα (ser32/36) (Cat. No. #9246) and phospho-p65 (ser536) (Cat. No. #3033) were provided by Cell Signaling and Neuroscience (Danvers, MA, USA). Sigma-Aldrich (St. Louis, MO, USA) provided the chemical inhibitors used in current study, including Wortmannin (Cat. No. W1628), LY294002 (Cat. No. L9908), AktI (Cat. No. A6730), TPCK (Cat. No. T4376), and PDTC (Cat. No. P8765). R&D Systems (Minneapolis, MN, USA) supplied recombinant human TSP2 (Cat. No. 1635-T2-050). shRNAs for integrins α and β3 and their respective controls were obtained from the National RNAi Core Facility Platform (RNAi Core, Academia Sinica, Taiwan).
Stratagene (La Jolla, CA, USA) provided the NF-κB luciferase plasmid. Dr. Wen-Mei Fu (National Taiwan University, Taipei, Taiwan) kindly gifted the dominant-negative mutants of p85 and Akt. Promega (Madison, MA, USA) supplied the pSV-β-galactosidase vector and the luciferase assay kit. The chemicals used in the current research were supplied by Sigma-Aldrich (St. Louis, MO, USA).

**Clinical Samples**
The Institutional Review Board (IRB) of Shin Kong Wu Ho-Su Memorial Hospital (Approval No. 20161209R) and China Medical University (Approval No. CMUH108-REC3-039) granted study approval and each study participant provided written informed consent. All methods were conducted in accordance with the provisions of the Declaration of Helsinki, as well as the IRB’s guidelines and regulations. Clinical samples were collected from patients meeting the following inclusion criteria: (1) aged over 20 years presenting with an accidental or sports injury requiring joint replacement and repair; or (2) degenerative arthritis. Exclusion criteria specified patients who did not satisfy either of these two categories. Synovial specimens were collected from donors with OA who have knee replacement surgery (OASFs) and nonarthritic synovial tissues obtained from healthy donors undergoing arthroscopy after trauma/joint derangement (NSFs).

**Cell Cultures**
The NSFs and OASFs cells were collected and maintained according to previous study procedures.30–32 Fresh synovial tissues were finely minced and digested in DMEM containing 2 mg/mL type II collagenase (Sigma-Aldrich, St. Louis, MO, USA) for 4 h at 37°C and under 5% CO2. After incubation with collagenase, the synovial fibroblasts were harvested by filtering through 70 μM nylon filters, centrifugation, and maintained in DMEM supplied with 10% FBS, 100 μg/mL streptomycin, and 100 U/mL penicillin. The cells were kept in a CO2 incubator at 37°C and 5% CO2. As previous study described,33 after isolating the cells from synovial tissues, the cells were characterized by immunofluorescence staining using antibody against vimentin, a typical fibroblast’s marker. More than 95% of the cells were fibroblasts. The synovial fibroblasts from passages of four to nine were used for the experiments.

**RNA Extraction and Quantitative Real-Time PCR**
The RNA of the treated cells was extracted by an easyBLUE™ Extraction Kit (iNTRON Biotechnology, Seoul, Korea). The total 2 μg RNA was used to synthesize cDNA by reverse transcription reaction using M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). SYBR Green Mastermix (KAPA Biosystem, Woburn, MA, USA) was used to perform quantitative real-time PCR (qPCR) analysis on StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The running protocol was 10 min at 95 °C, 15 s at 95 °C for 40 cycles, and finally 60 s at 60 °C. The primers used for detecting target genes were obtained from Sigma-Aldrich (St. Louis, MO, USA). Relative expressions of target genes were normalized to endogenous control GAPDH by using 2^ΔΔCt Method. All data shown were representative of three independent experiments. The sequence information of primers was provided in Supplementary Table 1.

**Western Blot**
Total proteins were extracted from the cells treated as indicated conditions by using RIPA buffer. Protein quantification and normalization were conducted by using a Thermo Scientific Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Waltham, USA). Proteins were loading to SDS-PAGE and running with 100 V for 90 mins, followed by transferring to PVDF membranes. The membranes were blocked with blocking buffer containing 5% BSA for 1 h at room temperature, followed by incubated the membranes with primary antibodies (1:1000) overnight at 4°C. After 3 washes by TBST, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000) for 1 h at room temperature. The membranes were stained by Amersham™ ECL™ Western Blotting Detection Reagents (GE Healthcare Life Sciences, Marlborough, MA, USA) and monitored by using a UVP ChemiDoc-It Imaging System (UVP Inc., Upland, CA, USA).

**Transfection and Reporter Gene Assay**
The reporter gene assay was used to monitor NF-κB transcriptional activity as described previously.34 Briefly, cells grown in 24 well plates were transfected with 0.8 μg reporter vector including NF-κB response element and
0.4 μg β-galactosidase expression vector by Lipofectamine® 3000 (LF3000; Invitrogen). 24-hour post-transfection, the cells were further treated with the indicated condition. Finally, the cells were lysed by reporter lysis buffer (Promega, Madison, WI, USA). The 20 μL lysates were mixed with 80 μL luciferase assay buffer (Promega), followed by detection of luminescence by using a microplate luminometer. The activity of β-galactosidase was used to evaluate transfection efficiency and in normalization of luciferase activity.

Immunofluorescence Staining
The cells grown in 8 well chamber slides were treated with the indicated condition. For immunofluorescence staining, the cells were fixed by 4% paraformaldehyde for 30 mins at room temperature, incubated in BSA blocking buffer containing 0.05% Triton X-100 for 30 mins at room temperature. Subsequently, the cells were incubated with p65 antibody (1:100) overnight at 4°C. After 3 times washing with PBS, the cells were further incubated with FITC-conjugated secondary antibody (1:100) for 1 h at room temperature (Leinco Technology Inc., St. Louis, MO, USA). Finally, the immunofluorescence signal was monitored by using a Nikon Ti2-E microscope system.

ACLT Animal Model
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Shin Kong Wu Ho-Su Memorial Hospital (Approval No. MOST1060009). All animal experimental procedures followed the Guide for the Care and Use of Laboratory Animals (Council of Agriculture, Executive Yuan, Taiwan). All experimental procedures were performed by two of the study authors, PC Chen and JF Liu, who have excellent experience in performing and replicating this animal model. The small sample size was chosen because the response of TSP2 neutralized antibody was investigated in OA animal model first time. A total of 25 male Sprague-Dawley (SD) rats (8 weeks) were purchased from the National Laboratory Animal Center (Taipei, Taiwan) and used for this study. The rats were randomly assigned to different groups; a) sham operation (n = 7), b) ACLT operation without treatment (n = 7), c) ACLT operation with TSP2 neutralizing antibody treatment (n = 7). Briefly, after animals were anesthetized with inhaled isoflurane and the joint capsules were opened, the ACL fibers were transected with a scalpel and the entire medial meniscus was excised using a medial parapatellar mini-arthrotomy. After surgery, the joints were washed with sterile PBS and sutured. The rats received 7 days of ampicillin treatment (50 mg/kg). The 4 rats were excluded because of the poor wound healing after surgery. One week later, they were administered an intra-articular injection of PBS (50 μL) containing a TSP2 neutralizing antibody (10 μg/mL); this was repeated after 1 week. All rats were allowed to move freely in plastic cages and were sacrificed 4 weeks after the ACLT procedure. PC Chen and JF Liu, who performed the operation were the only investigators aware of the experiment allocation. The research assistant (unaware of treatment) was responsible for the animal sacrifice, tissue collection, and histological analysis including Safranin O/fast green staining, immunohistochemistry staining, and ORASI score.

Histological Analysis
Paraffin-embedded sections were prepared from sacrificed rats. The sections were subjected to Safranin O/fast green staining to evaluate cartilage degradation, or incubated with a specific antibody against IL-6, as per our previous protocol. IL-6 antibody in the sections was detected by the NovoLink Polymer Detection Systems kit (Leica Biosystems, Wetzlar, Germany), according to the manufacturer’s protocol.

For Safranin O/fast green staining, briefly, the sections were stained with Safranin O/fast green, hematoxylin, and eosin to investigate the histopathological changes of all experiment groups under a light microscope. The cartilage destruction was evaluated according to the OARSI score system established by the International Association for Osteoarthritis Research. The OARSI score system includes 6 grades (Grade 0 = no cartilage degeneration; Grade 1 = Minimal degeneration, 5–10% of the total projected cartilage area affected by matrix or chondrocyte loss; Grade 2 = Mild degeneration, 11–25% affected; Grade 3 = Moderate degeneration, 26–50% affected; Grade 4 = Marked degeneration, 51–75% affected; Grade 5 = Severe degeneration, greater than 75% affected). The scoring was evaluated blindly by two individuals and the scores were averaged to minimize observer bias.

Statistical Analysis
Statistical data were analyzed using SigmaPlot version 12.0 (Systat Software, Inc., San Jose, CA). All values reported are means ± standard deviations (S.D) of independent experiments. Statistical analysis of two samples was performed
using the Student’s *t*-test. In the case of the experiment groups more than two groups, statistical analysis was performed using one-way analysis of variance (ANOVA) with the Fisher’s Least Significant Difference (LSD) post-hoc test. In all cases, *p* < 0.05 presented statistical significance.

**Results**

**TSP2 Induced Significant Increases in IL-6 Expression**

As shown in Figure 1A and B, evidence from Western blot and qPCR assays reveals higher levels of TSP2 protein and mRNA expression in OASFs than in human normal synovial fibroblasts (NSFs). As previous research has shown high quantities of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) as well as endothelial adhesion molecules (ICAM-1 and VCAM-1) in OA fibroblast lines, consistent with our results (Supplementary Figure 1). Therefore, we hypothesized that the same phenomenon might be observed in TSP2-directed OA pathogenesis. The levels of IL-6 expression were significantly higher than those for all other molecules (Figure 1D), whereas TSP2 had no effect upon IL-6 expression in NSFs (Figure 1C). TSP-induced increases in IL-6 expression were concentration-dependent (Figure 1E and F). These data suggest that OASFs are more sensitive than normal SFs to TSP2 and that TSP2 effectively increases IL-6 production in OASFs.

**A TSP2/Integrin αvβ3 Interaction Was Linked to IL-6 Expression in OASFs**

TSP2 is reported to interact with various integrins to exert its biological functions, including integrin αvβ3,22,37,38 αβ1,39 and β1.40 The TSP2 arginine-glycine-aspartic acid sequence interacts with cell-associated integrin αvβ3 and heparan sulfate proteoglycans and also binds to the low-density lipoprotein receptor-related protein that modulates TSP2 concentrations in the pericellular environment via endocytotic and lysosomal protein degradation processes.41 Our results found that both basal expression levels of integrin αv and β3 were higher in OASFs than NSFs (Figure 2A), suggesting their important role in OA pathogenesis. We, therefore, examined the effect of integrin αvβ3 neutralization upon TSP2-induced increases in IL-6 expression in human OASFs. Our data show that the integrin αvβ3 antibody...
substantially inhibited such increases (Figure 2B and C). This process was dramatically inhibited when OASFs were transfected with integrin αν and integrin β3 shRNAs (Figure 2D). Thus, it appears that the effects of TSP2 upon IL-6 expression occur via the activation of integrin ανβ3.

**TSP2-Mediated IL-6 Production Involves PI3K/Akt Signaling**

The PI3K/Akt signaling pathway is one of several that are activated by the engagement of integrin ανβ3 with its ligand. Furthermore, IL-6 expression in prostate cancer cells and human lung fibroblasts is mediated by PI3K/Akt signaling. We, therefore, examined whether TSP2-induced increase of IL-6 expression involves PI3K and Akt signaling. Pretreatment with LY294002, Wortmannin, and AktI all markedly reduced the effects of TSP2 upon IL-6 expression (Figure 3A–C), while TSP2 treatment significantly increased p85 and Akt phosphorylation (Figure 3D). The OASFs which transfected with a p85 or an Akt dominant-negative (DN) mutant showed obvious inhibition of TSP2-induced IL-6 expression (Figure 3E). Thus, blocking PI3K and Akt activity appears to inhibit TSP2-mediated IL-6 expression. Moreover, these findings indicate that TSP2 stimulates IL-6 production via the activation of integrin ανβ3, which subsequently activates the PI3K/Akt signaling pathway in OASFs.

**NF-κB is Involved in TSP2-Induced Stimulation of IL-6 Expression**

NF-κB activation can induce IL-6 in various cell types. To examine whether NF-κB activity in the signaling pathway mediates TSP2-induced increases in IL-6 expression, OASFs were pretreated separately with the NF-κB inhibitor (PDTC; 5 µM) and 1xB protease inhibitor (TPCK; 5 µM) before TSP2 application. The data showed that pretreatment with inhibitors of NF-κB signal cascade dramatically abrogated IL-6 mRNA and protein expression in response to TSP2 incubation (Figure 4A and B).
Moreover, TSP2 treatment time-dependently upregulated IKKα/β, IκBα, and p65 phosphorylation in OASFs (Figure 4C). Upon IKKα and IKKβ mutant transfection, TSP2-induced stimulation of IL-6 expression was significantly reduced in OASFs (Figure 4D).

Pretreatment with integrin αvβ3 monoclonal antibody (mAb), LY294002, Wortmannin, and AktI all reversed the nuclear translocation of p65, which was induced by TSP2 incubation in OASFs (Figure 5A), and abolished phosphorylation of the NF-κB signaling cascade (Figure 5B). We also found that TSP2 stimulated NF-κB promoter activity (Figure 5C), which was abolished when the OASFs were pretreated with integrin αvβ3 mAb, LY294002, Wortmannin, and AktI (Figure 5D). Our evidence suggests that TSP2-mediated increases of IL-6 expression in human OASFs are dependent upon integrin αvβ3 and PI3K/Akt-NF-κB pathway activation.

### TSP2-Targeting Therapy Alleviates ACLT-Induced Osteoarthritis in vivo

Finally, to confirm the therapeutic value of TSP2 in OA, IL-6 expression was assessed in the presence of TSP2 mAb. The results indicated that TSP2 neutralizing antibody dose-dependently abolished IL-6 expression in OASFs (Figure 6A and B). Meanwhile, the ACLT-induced OA in rat model, an animal model suitable for evaluating OA pathogenesis, was conducted to evaluate whether TSP2 target therapy could alleviate OA progression in vivo. Our result showed that treatment with TSP2 neutralizing antibody attenuated articular cartilage...
degradation and IL-6 expression, as proved by Safranin O/fast green staining and immunohistochemistry respectively (Figure 6C–E), demonstrating the therapeutic potential of TSP2 in OA progression in vivo.

**Discussion**

TSP2 was proposed as prognosis marker in liver fibrosis,\(^47,48\) non-alcoholic fatty liver disease,\(^49\) and different cancers.\(^50–53\) This study demonstrates that TSP2 is an important player in OA pathogenesis, with a positive correlation observed between TSP2 expression and synovial tissue inflammation, suggesting TSP2 could be developed as novel osteoarthritis marker. The pre-clinical experiments, which utilized TSP2 neutralizing antibody to ameliorate cartilage destruction in OA animal model, also showed the promising response. The results provided therapeutic opportunity of TSP2 in OA treatment.

Evidence implicates TSP2 in the regulation of various biological processes, such as thrombosis,\(^54\) angiogenesis,\(^55\) proteolytic enzyme release, control of inflammatory cell influx, and activation of the inflammatory response.\(^56,57\) Previous research has demonstrated TSP involvement in OA pathogenesis, such as TSP1,\(^17\) and a positive correlation between levels of TSP4 protein expression and disease severity.\(^19\) Moreover, TSP2 displays antiangiogenic activity and suppresses autoimmune inflammation in RA synovial tissue.\(^29\) COMP/TSP5 is also a well-established cartilage destruction marker in osteoarthritis.\(^58\) Several reports have proposed that COMP/TSP5 is a promising diagnostic and prognostic marker, as well as disease severity. COMP/TSP5 has shown promise as a diagnostic and prognostic indicator and as a marker of the disease severity and the effect of treatment.\(^59\) COMP/TSP5 was proved to exert its biological function by interaction with integrin α_vβ_3 on chondrocytes,\(^60\) which in accordance with our current finding that TSP2 promoted IL-6 expression by binding to integrin α_vβ_3. Interestingly, we found expression levels of integrin α_v and β_3 were higher in OASFs

---

**Figure 4** NF-κB is required for IL-6 production in response to TSP2 stimulation. (A and B) OASFs were incubated with PDTC (10 µM) or TPCK (10 µM) for 30 min, then stimulated with TSP2 (30 ng/mL) for 24 h. The expression levels of IL-6 in OASFs were examined by Western blot and qPCR assays. (C) OASFs were stimulated with TSP2 (30 ng/mL) for the various time courses; the phosphorylated forms of IKKα/β, IκBα, and p65 were monitored by Western blot analysis. (D) OASFs transfected with IKKα and IKKβ mutants were stimulated with TSP2 (30 ng/mL) for 24 h. IL-6 expression was investigated by qPCR. Results are expressed as the mean ± SD (n ≥ 5). *p < 0.05 compared with controls; †p < 0.05 compared with the TSP2-treated group.

**Abbreviations:** TSP-2, thrombospondin-2; IL-6, interleukin-6; DN, dominant mutant.
than NSFs, which explains that OASFs had obvious response to TSP2 stimulation.

The initiation and progression of OA depends upon synovial inflammation, which produces proinflammatory mediators that contribute to degradation of the cartilage matrix. For example, the expression of IL-1β in synovial cells initiates an inflammatory cascade that leads to joint damage, while IL-6 perpetuates inflammation and destruction in the synovium. Moreover, TNF-α contributes to inflammation and joint destruction in RA synovial fluid and induces ICAM-1 and VCAM-1 expression in endothelial cells. Here, we found TSP2 neutralized antibody ameliorated ACLT-induced OA model in rats by attenuating articular cartilage degradation and IL-6 expression. However, the other molecules which are involved in OA pathogenesis should be investigated to evaluate the therapeutic effects of TSP2 on OA progression.

An important driver of inflammation is the PI3K/Akt signaling pathway, which mediates many cellular functions, including cell apoptosis, mobility, and autophagic reflex. By regulating the PI3K/AKT pathway, TSP2 knockdown inhibits the proliferative, migratory, and

---

Figure 5 The integrin αvβ3/PI3K/Akt pathway mediates NF-κB activation in response to TSP2 treatment. (A) OASFs were incubated with integrin αvβ3 mAb, LY294002, Wortmannin, or AktI for 30 min, followed by incubated with TSP2 (30 ng/mL) for 60 min. The treated cells were subjected to immunofluorescence staining to detect p65 localization. (B) OASFs were pretreated with integrin αvβ3 mAb, LY294002, Wortmannin, or AktI for 30 min, then stimulated with TSP2 (30 ng/mL) for 60 min, and phosphorylated form of p65 was measured by Western blot analysis. (C and D) OASFs transfected with NF-κB reporter vector were incubated with different doses of TSP2 (C) or incubated with TSP2 (30 ng/mL) in presence of the pathway inhibitor (LY294002, Wortmannin, AktI, PDTC, or TPCK) (D). The reporter assay was conducted to determine NF-κB transcriptional activation. The β-galactosidase activity was used as an indicator of transfection efficiency. Results are expressed as the mean ± SD (n ≥ 5). *p < 0.05 compared with controls; #p < 0.05 compared with the TSP2-treated group.

Abbreviation: TSP-2, thrombospondin-2.
invasive capabilities of gastric cancer cells and facilitates cellular apoptosis.\(^{67}\) Our investigation demonstrates that PI3K and Akt inhibitors inhibit TSP2-induced IL-6 expression, while p85 and Akt mutants reduced IL-6 expression in OASFs. Furthermore, the incubation of OASFs with TSP2 upregulated the phosphorylation of PI3K and Akt. Our evidence supports the involvement of the PI3K/Akt signaling pathway in TSP2-mediated effects upon IL-6 expression in OASFs.

Since NF-κB is a major downstream signaling molecule of the PI3K/Akt pathway,\(^{68,69}\) we explored the extent of NF-κB involvement in TSP2-mediated IL-6 production in OASFs. We found that treatment with NF-κB pathway inhibitors or mutants downregulated TSP2-enhanced IL-6 production. TSP2 treatment of OASFs increased NF-κB phosphorylation. Following PI3K or Akt inhibitor treatment, TSP2-induced cellular p65 phosphorylation was downregulated, which indicates that TSP2 stimulates the production of IL-6 in OASFs via the PI3K/Akt-NF-κB signaling cascade.

**Conclusions**

In conclusion, thrombospondin-2 increases interleukin-6 production by integrin α\(v\)/β3/PI3K/Akt/NF-κB signal cascade (Figure 7), which gives us more insight into the mechanisms driving osteoarthritis pathogenesis and is expected to assist with the development of more efficacious osteoarthritis therapy.
Figure 7 Schematic diagram illustrates the mechanism whereby TSP2 promotes IL-6 expression in OASFs. Thrombospondin-2 increases interleukin-6 production by integrin α₁β₃/PI3K/Akt/NF-κB signal cascade.

Data Accessibility
The datasets used and analysed in this study are available from the corresponding authors on reasonable request.

Acknowledgments
This work was supported by grants from Taiwan’s Ministry of Science and Technology (MOST-108-2314-B-002-211-MY3, MOST-107-2314-B-341-003, MOST106-2314-B-341-001-MY3) and the Shin-Kong Wu Ho-Su Memorial Hospital (SKH-8302-106-0401). We would like to thank Iona J. MacDonald in China Medical University for her English language revision of this manuscript. We thank the staff of the Eighth Core Lab, Department of Medical Research, National Taiwan University Hospital for technical support during the study.

Disclosure
The authors state no conflict of interest in this work.

References


